BCG, a leading U.S. consulting firm, released one of its 2020 China Pharmaceutical Innovation Reports - China Pharmaceutical Innovation: The Road to Rise.

The report divides the future innovation development path of Chinese pharmaceuticals into Innovation 1.0, 2.0 and 3.0 according to different forms of innovation.

Innovation 1.0 mainly refers to fast-follow innovation, which accounts for about 79% of total innovation. Fast-follow" is still the main form of innovation in China, and under the main theme of fast-follow, China will achieve "faster", "earlier" and "better". Follow up.

Innovation 2.0 refers to combination therapies, dual antibodies, and indication expansion, accounting for 12% of total innovation. China is accelerating its pace of participation in combination therapies and will emerge as an area of indication expansion for high prevalence in China.

Innovation 3.0 refers to completely new targets, technologies, and accounts for 9% of total innovation. China is expected to make a jump in some areas of novel technologies in addition to the first signs of growth, driven by a combination of basic research and translational medicine development.

In Innovation 2.0, ExMab®, the novel BsAb antibody platform of ExcelMab, has been recognized by BCG as a representative bispecific antibody technology platform in China.

The ExMab® platform is one of the world's top bispecific antibody platforms, which utilizes structure-based protein engineering technology to fuse two different specific antibody molecules together to form a stable, very low immunogenic drug entity.

The ExMab® platform patents are currently licensed in the US, Japan, Korea, Canada, and Australia.

ExMab® has demonstrated excellent qualities in mismatch precention, molecular stability, purification process, and immunogenicity, and stands out from the crowd of bispecific antibody platforms in China.